Lercanidipina Ciclum

Lercanidipine, the active ingredient in Lercanidipina Ciclum, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk. It is indicated for patients with primary (essential) hypertension and may be used as monotherapy or in combination with other antihypertensives.

GNH USA supplies Lercanidipina Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to global healthcare providers.

Lercanidipine is an antihypertensive calcium‑channel blocker that selectively relaxes arterial smooth muscle, thereby decreasing peripheral vascular resistance and helping to control elevated blood pressure in adults.

Hypertension (essential): provides sustained reduction of systolic and diastolic pressures, supporting long‑term blood‑pressure management either as monotherapy or in combination with other antihypertensive agents. Isolated systolic hypertension: especially beneficial in older patients by lowering systolic pressure and reducing cardiovascular strain.

Lercanidipine may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Angioedema - Myocardial infarction

When prescribing or dispensing Lercanidipine, consider the following precautions. - Dose adjustment: required in hepatic impairment - Avoid abrupt discontinuation: may cause rebound hypertension - Monitor blood pressure: ensure therapeutic response - Caution in elderly: increased sensitivity to hypotension - Store at ambient temperature: keep in original container, protect from moisture

Lercanidipine can interact with several drug classes; assess the clinical relevance before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels - Concomitant use with other potent vasodilators: risk of additive hypotension

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy - Non‑steroidal anti‑inflammatory drugs: may increase risk of renal impairment - Diuretics: monitor electrolytes and blood pressure